We have been unwavering in our conviction that RNA data is key to the development of personalized treatments, which is why we have been sequencing RNA since the very beginning. Receiving a PLA code from AMA for the PurIST test is a meaningful step forward in carving a path for reimbursement for these kinds of RNA-based tests.
We’re excited to announce that our PurIST℠ algorithmic test has received a proprietary laboratory analysis (PLA) code from the American Medical Association (AMA). The new code will be effective on October 1, 2024. The PurIST℠ PLA code is the first common procedural terminology (CPT) code created to describe an algorithm-only analysis from previously-sequenced, laboratory developed test (LDT), transcriptomic (RNA) data, representing a meaningful step towards reimbursement for AI-enabled algorithms. Learn more: https://tempus.co/3zx5QmZ
Very cool, and well done
Huge win for Tempus AI!
Totally agree on this aproach!
Congrats! PLA codes are no easy feat.
Moving forward!
Exciting development, congrats!
That is very inspiring Eric!
Congratulations 🎉
CEO @ Boudicca Dx | Precision Medicine Consulting | Regulatory Professional | Clinical Biomarker Development | Companion Diagnostics | IVD Product Development | Clinical Molecular Technologist (LDTs) | Scientific Advisor
4moCould not agree more and so much more to come for RNA-based diagnostics! RNA has already proven its value for fusion detection, innovative prognostic and predictive signature development and offers a comprehensive solution for expression biomarkers maximizing tissue use. I am excited to see what cfRNA liquid biopsy will unveil-so much yet to discover in the blood! 🩸